BeOne Medicines AG (BVMF:B1ME34)

Market Cap	204.42B +45.8%
Revenue (ttm)	26.50B +50.4%
Net Income	365.33M
EPS	3.12
Shares Out	n/a
PE Ratio	559.54
Forward PE	66.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Average Volume	162
Open	72.73
Previous Close	70.00
Day's Range	72.73 - 72.73
52-Week Range	41.50 - 72.73
Beta	n/a
RSI	61.58
Earnings Date	Apr 15, 2026

About BeOne Medicines AG

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 11,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: B1ME34

Financial Performance

In 2024, BeOne Medicines AG's revenue was $3.81 billion, an increase of 54.96% compared to the previous year's $2.46 billion. Losses were -$644.79 million, -26.87% less than in 2023.

Financial numbers in USD